Cell Therapy of Cancer

  • Kewal K. Jain


Cell therapy is the prevention or treatment of human disease by the administration of cells that have been selected, multiplied, and pharmacologically treated or altered outside the body (ex vivo). The scope of cell therapy can be broadened to include methods, pharmacological as well as non-pharmacological, to modify the function of intrinsic cells of the body in vivo for therapeutic purposes. The aim of cell therapy is to replace, repair, or enhance the function of damaged tissues or organs. The cells used can originate from the patient or from a donor or from another species. Other sources include cell lines and cell from patients’ tumors to make cancer vaccines. Cells can be encapsulated in selectively permeable membranes that block entry of immune mediators but allow outward diffusion of active molecules produced by the cells. Genetic engineering of cells is part of ex vivo gene therapy. The cells may be introduced by various routes into the body and selectively implanted at the site of action. More recently, cell therapies have expanded to replace some conventional procedures. Bone marrow (BM) transplants are being replaced by peripheral blood stem cell (PBSC) transplants. Most of the interest in cell therapy centers on stem cells. The reason for the surge of interest in cell therapy is that cells often do a job better than any chemical could. Cell therapy is described in detail in a special report on this topic (Jain 2013).


Stem Cell Natural Killer Cell Cancer Stem Cell Umbilical Cord Blood Peripheral Blood Stem Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Aboody KS, Bush RA, Garcia E, et al. Development of a Tumor-Selective Approach to Treat Metastatic Cancer. PLoS ONE 2006;1:e23.CrossRefGoogle Scholar
  2. Ahmed N, Abubaker K, Findlay JK. Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets. Mol Aspects Med 2013 Jun 25;pii: S0098-2997(13)00042-3.Google Scholar
  3. Anasetti C, Logan BR, Lee SJ, et al. Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors. N Engl J Med 2012;367:1487-96.CrossRefGoogle Scholar
  4. Arina A, Murillo O, Dubrot J, et al. Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer. Exp Opin Biol Ther 2007;7:599-615.CrossRefGoogle Scholar
  5. Batlle M, Oriol A, Ribera JM, et al. Neurologic complications following hematopoietic stem cell transplantation. Study of 14 patients. Med Clin (Barc) 2005;125:697-9.CrossRefGoogle Scholar
  6. Busca A. The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation. Expert Opin Biol Ther 2011;11:687-97.CrossRefGoogle Scholar
  7. Chaffer CL, Brueckmann I, Scheel C, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. PNAS 2011;108:7950-5.CrossRefGoogle Scholar
  8. Chen MJ, Yokomizo T, Zeigler BM, et al. Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter. Nature 2009;457:887-91.CrossRefGoogle Scholar
  9. Chen X, Barfield R, Benaim E, et al. Prediction of T-cell reconstitution by assessment of T-cell receptor excision circle before allogeneic hematopoietic stem cell transplantation in pediatric patients. Blood 2005;105:886-93.CrossRefGoogle Scholar
  10. Chen X, Zhang J, Zhang Z, et al. Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. Hum Pathol 2013;44:2373-84.Google Scholar
  11. Cheng H, Kastrup CJ, Ramanathan R, et al. Nanoparticulate cellular patches for cell-mediated tumoritropic delivery. ACS Nano 2010;4:625-31.CrossRefGoogle Scholar
  12. Choi MR, Stanton-Maxey KJ, Stanley JK, et al. A cellular Trojan horse for delivery of therapeutic nanoparticles into tumors. Nano Lett 2007;7:3759-65.CrossRefGoogle Scholar
  13. Dai LJ, Sun XY, Luo J. Mesenchymal Stem Cells: Prospects for Cancer Therapy. In Danquah MK, Mahato RI (eds) Emerging Trends in Cell and Gene Therapy. Springer, New York, 2013: 271-86.CrossRefGoogle Scholar
  14. Dwyer RM, Kerin MJ. Mesenchymal stem cells and cancer: tumor-specific delivery vehicles or therapeutic targets? Hum Gene Ther 2010;21:1506-12.CrossRefGoogle Scholar
  15. Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007; 369:1947-54.CrossRefGoogle Scholar
  16. Gallagher G, Forrest DL. Second Solid Cancers After Allogeneic Hematopoietic Stem Cell Transplantation. Cancer 2007;109:84-92.CrossRefGoogle Scholar
  17. Gooley TA, Chien JW, Pergam SA, et al. Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med 2010; 363:2091-101.CrossRefGoogle Scholar
  18. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1:313-23.CrossRefGoogle Scholar
  19. Ho VT, Vanneman M, Kim H, et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. PNAS 2009;106:15825-30.CrossRefGoogle Scholar
  20. Jain KK. Cell therapy: technologies, markets and companies. Basel: Jain PharmaBiotech; 2013.Google Scholar
  21. Komarova S, Kawakami Y, Stoff-Khalili MA, et al. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006;5:755-66.CrossRefGoogle Scholar
  22. Kucerova L, Altanerova V, Matuskova M, et al. Adipose Tissue–Derived Human Mesenchymal Stem Cells Mediated Prodrug Cancer Gene Therapy. Cancer Res 2007;67:6304-13.CrossRefGoogle Scholar
  23. Ledran MH, Krassowska A, Armstrong L, et al. Efficient hematopoietic differentiation of human embryonic stem cells on stromal cells derived from hematopoietic niches. Cell Stem Cell 2008;3:85-98.CrossRefGoogle Scholar
  24. Leen AM, Tripic T, Rooney CM. Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther 2010;10:337-51.CrossRefGoogle Scholar
  25. Lian X, Hsiao C, Wilson G, et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A 2012;109:E1848-57.CrossRefGoogle Scholar
  26. Loughran SJ, Kruse EA, Hacking DF, et al. The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. Nature Immunology 2008;9:810-9.CrossRefGoogle Scholar
  27. Mani SA, Yang J, Brooks M, et al. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. PNAS 2007;104:10069-74.CrossRefGoogle Scholar
  28. Massberg S, Schaerli P, Knezevic-Maramica I, et al. Physiological recirculation of hematopoietic stem and progenitor cells through blood, lymph and extramedullary tissues. Cell 2007;131:994-1008.CrossRefGoogle Scholar
  29. Mercadal S, Briones J, Xicoy B, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008;19:958-63.CrossRefGoogle Scholar
  30. Milpied N, Deconinck E, Gaillard F, et al. Initial Treatment of Aggressive Lymphoma with High-Dose Chemotherapy and Autologous Stem-Cell Support. NEJM 2004;350:1287-95.CrossRefGoogle Scholar
  31. Müller AM, Shashidhar S, Küpper NJ, et al. Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity. PNAS 2012;109:5820-5.CrossRefGoogle Scholar
  32. Muthana M, Scott SD, Farrow N, et al. A novel magnetic approach to enhance the efficacy of cell-based gene therapies. Gene Therapy 2008;15:902-10.CrossRefGoogle Scholar
  33. Narasipura SD, Wojciechowski JC, Charles N, et al. P-Selectin coated microtube for enrichment of CD34+ hematopoietic stem and progenitor cells from human bone marrow. Clin Chem 2008;54:77-85.CrossRefGoogle Scholar
  34. Narula J, Smith AM, Gottgens B, Igoshin OA. Modeling Reveals Bistability and Low-Pass Filtering in the Network Module Determining Blood Stem Cell Fate. PLoS Comput Biol 2010;6(5): e1000771.CrossRefGoogle Scholar
  35. Nolan D, Ciarrocchi A, Mellick AS, et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes & Development 2007;21:1546-58.CrossRefGoogle Scholar
  36. Ringden O, Labopin M, Gorin NC, et al. Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukemia, an Acute Leukemia Working Party analysis in 2262 patients. J Int Med 2012;47:1171-7.Google Scholar
  37. Rodrigues DB, Chammas R, Malavasi NV, et al. Anti-tumor therapy with macroencapsulated endostatin producer cells. BMC Biotechnology 2010;10:19.CrossRefGoogle Scholar
  38. Sehl ME, Sinsheimer JS, Zhou H, Lange KL. Differential Destruction of Stem Cells: Implications for Targeted Cancer Stem Cell Therapy. Cancer Res 2009;69:9481-9.CrossRefGoogle Scholar
  39. Srivastava S, Lundqvist A, Childs RW. Natural killer cell immunotherapy for cancer: a new hope. Cytotherapy 2008;10:775-83.CrossRefGoogle Scholar
  40. Stachowiak MK, Maher PA, Stachowiak EK. Integrative nuclear signaling in cell development—a role for FGF receptor-1. DNA Cell Biol 2007;26:811-26.CrossRefGoogle Scholar
  41. Suzuki A, Raya A, Kawakami Y, et al. Maintenance of embryonic stem cell pluripotency by Nanog-mediated reversal of mesoderm specification. Nat Clin Pract Cardiovasc Med 2006;3 Suppl 1:S114-22.CrossRefGoogle Scholar
  42. Taoudi S, Gonneau C, Moore K, et al. Extensive hematopoietic stem cell generation in the AGM region via maturation of VE-cadherin+CD45+ pre-definitive HSCs. Cell Stem Cell 2008;3:99-108.CrossRefGoogle Scholar
  43. Taskinen M, Saarinen-Pihkala UM, Hovi L, et al. Bone health in children and adolescents after allogeneic stem cell transplantation: high prevalence of vertebral compression fractures. Cancer 2007;110:442-51.CrossRefGoogle Scholar
  44. Tefferi A. Myelodysplastic Syndromes. NEJM 2009;361:1872-85.CrossRefGoogle Scholar
  45. Thanendrarajan S, Kim Y, Schmidt-Wolf I. New adoptive immunotherapy strategies for solid tumours with CIK cells. Expert Opin Biol Ther 2012;12:565-72.CrossRefGoogle Scholar
  46. Tsao GJ, Allen JA, Logronio KA, et al. Purified hematopoietic stem cell allografts reconstitute immunity superior to bone marrow. PNAS 2009;106:3288-93.CrossRefGoogle Scholar
  47. Tykodi SS, Sandmaier BM, Thompson JA. Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after. Expert Opin Biol Ther 2011;11:763-73.CrossRefGoogle Scholar
  48. Vaish M. Mismatch repair deficiencies transforming stem cells into cancer stem cells and therapeutic implications. Mol Cancer 2007;6(1):26.CrossRefGoogle Scholar
  49. van Egmond M. Neutrophils in antibody-based immunotherapy of cancer. Expert Opin Biol Ther 2008;8:83-94.CrossRefGoogle Scholar
  50. Voss M, Bischof F. Recurrent myelitis after allogeneic stem cell transplantation. Report of two cases. BMC Neurol 2010;10:76. doi: 10.1186/1471-2377-10-76.CrossRefGoogle Scholar
  51. Wang GP, Guan YS, Jin XR, et al. Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites. J Gastroenterol Hepatol 2010;25:985-90.CrossRefGoogle Scholar
  52. Widschwendter M, Fiegl H, Egle D, et al. Epigenetic stem cell signature in cancer. Nat Genetics 2007;39:157-8.CrossRefGoogle Scholar
  53. Yilmaz OH, Valdez R, Theisen BK, et al. PTEN dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006;441:475-82.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Kewal K. Jain
    • 1
  1. 1.Jain PharmaBiotechBaselSwitzerland

Personalised recommendations